NO964113L - Anvendelse av fettsyreestre som bioadhesive substanser - Google Patents

Anvendelse av fettsyreestre som bioadhesive substanser

Info

Publication number
NO964113L
NO964113L NO964113A NO964113A NO964113L NO 964113 L NO964113 L NO 964113L NO 964113 A NO964113 A NO 964113A NO 964113 A NO964113 A NO 964113A NO 964113 L NO964113 L NO 964113L
Authority
NO
Norway
Prior art keywords
fatty acid
acid esters
bioadhesive
mucosa
glyceryl
Prior art date
Application number
NO964113A
Other languages
English (en)
Other versions
NO964113D0 (no
Inventor
Jens Hansen
Nielsen Lise Sylvest
Tomas Norling
Original Assignee
Dumex Ltd As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dumex Ltd As filed Critical Dumex Ltd As
Publication of NO964113D0 publication Critical patent/NO964113D0/no
Publication of NO964113L publication Critical patent/NO964113L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Fettsyreestrene har molekylvekter under ca. 1000 dalton, og fettsyre-komponenten av fettsyreesteren er en mettet eller umettet fettsyre med et totalt antall karbonatomer på fra 8 til 22. Spesielt egnede fettsyreestere for anvendelse ifølge oppfinnelsen, er fettsyreestere som er valgt fra gruppen bestående av fettsyreestere av polyhydriske alkoholer, fettsyre- estere av hydroksykarboksylsyrer, fettsyreestere av monosakkarider, fettsyreestere av glycerylfosfat-derivater, fettsyreestere av glycerylsulfat-derivater, og blandinger derav. Utmerkede bioadhesive egenskaper er observert for fettsyrer av glyceryl-monooleat, glyceryl-monolinoleat eller glyceryl-monolinolenat. Det er beskrevet metoder for administrering av en aktiv eller beskyttende substans til uskadet eller skadet hud eller mukosa hos et dyr så som et menneske, ved å kombinere den aktive eller beskyttende substansen med en bioadhesiv fettsyreester. Slimhinnen kan være oral, aural, nasal, lunge-, gastrointestinal, vaginal eller rektal mukosa. Administreringen kan også gjøres til kroppshulrom så som munnen, f.eks ved bukkal administrering.
NO964113A 1994-03-30 1996-09-27 Anvendelse av fettsyreestre som bioadhesive substanser NO964113L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK37094 1994-03-30
PCT/DK1995/000143 WO1995026715A2 (en) 1994-03-30 1995-03-29 Use of fatty acid esters as bioadhesive substances

Publications (2)

Publication Number Publication Date
NO964113D0 NO964113D0 (no) 1996-09-27
NO964113L true NO964113L (no) 1996-11-27

Family

ID=8092745

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964113A NO964113L (no) 1994-03-30 1996-09-27 Anvendelse av fettsyreestre som bioadhesive substanser

Country Status (12)

Country Link
US (1) US5955502A (no)
EP (1) EP0752855B1 (no)
JP (1) JP4137179B2 (no)
AT (1) ATE180971T1 (no)
AU (1) AU685262B2 (no)
CA (1) CA2186750C (no)
DE (1) DE69510190T2 (no)
DK (1) DK0752855T3 (no)
ES (1) ES2135723T3 (no)
FI (1) FI963867A (no)
NO (1) NO964113L (no)
WO (1) WO1995026715A2 (no)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997013528A1 (en) * 1995-10-12 1997-04-17 Gs Development Ab A pharmaceutical composition for administration of an active substance to or through a skin or mucosal surface
GB9617001D0 (en) * 1996-08-13 1996-09-25 Tillotts Pharma Ag Oral composition
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
PT942780E (pt) * 1997-09-09 2003-11-28 Lyotropic Therapeutics Inc Particulas revestidas processos de obtencao e uso
EA003512B1 (ru) * 1998-03-20 2003-06-26 Кова Ко., Лтд. Желудочная и/или дуоденальная клейкая лекарственная форма
ITMI981528A1 (it) * 1998-07-03 2000-01-03 Recordati Ind Chimica E Farma Formulazioni topiche di aciclovir
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
PT1183014E (pt) * 1999-06-14 2003-12-31 Cosmo Spa Composicoes farmaceuticas orais de libertacao controlada e de dissimulacao de sabor
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
KR100381622B1 (ko) * 2000-08-30 2003-04-26 디디에스텍주식회사 자극성을 줄인 염기성 약물의 구강 투여 조성물
US6887493B2 (en) * 2000-10-25 2005-05-03 Adi Shefer Multi component controlled release system for oral care, food products, nutraceutical, and beverages
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
US6565873B1 (en) * 2000-10-25 2003-05-20 Salvona Llc Biodegradable bioadhesive controlled release system of nano-particles for oral care products
CA2449415A1 (en) * 2001-04-20 2002-10-31 Lavipharm Laboratories Inc. Intraoral delivery of nicotine for smoking cessation
CN1236831C (zh) * 2001-05-21 2006-01-18 茵捷特数码浮质有限公司 用于经肺部途径递送蛋白质的组合物
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
FR2827517B1 (fr) * 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
CA2508907A1 (en) * 2001-11-08 2003-05-15 Atrium Medical Corporation Intraluminal device with a coating containing a therapeutic agent
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20040018237A1 (en) * 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
KR100533460B1 (ko) * 2002-07-20 2005-12-08 대화제약 주식회사 난용성 약물의 가용화용 점막흡착성 조성물, 이를 이용한난용성 약물의 가용화용 제형 및 이들의 제조 방법
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
PT1638516E (pt) * 2003-07-01 2010-06-17 Skinsure Internat Ltd Formulação barreira que compreende uma emulsão à base de silicone
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
JP2007504826A (ja) * 2003-09-09 2007-03-08 スリーエム イノベイティブ プロパティズ カンパニー 濃厚な抗菌性組成物および方法
US20050053593A1 (en) * 2003-09-09 2005-03-10 3M Innovative Properties Company Antimicrobial compositions and methods
US20050175679A1 (en) * 2004-02-10 2005-08-11 Michael Moshman Controlled release formulations
DE602005008247D1 (de) * 2004-06-04 2008-08-28 Camurus Ab Flüssige depotformulierungen
US20070196457A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more volatile solvent-containing compositions and methods for dermal delivery of drugs
US8907153B2 (en) * 2004-06-07 2014-12-09 Nuvo Research Inc. Adhesive peel-forming formulations for dermal delivery of drugs and methods of using the same
US20070196452A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
US20070196453A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Two or more non-volatile solvent-containing compositions and methods for dermal delivery of drugs
US8741332B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for dermally treating neuropathic pain
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
US20070190124A1 (en) * 2004-06-07 2007-08-16 Jie Zhang Two or more solidifying agent-containing compositions and methods for dermal delivery of drugs
US8741333B2 (en) * 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
WO2006036970A2 (en) * 2004-09-28 2006-04-06 Atrium Medical Corporation Method of thickening a coating using a drug
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060088596A1 (en) 2004-09-28 2006-04-27 Atrium Medical Corporation Solubilizing a drug for use in a coating
US8312836B2 (en) 2004-09-28 2012-11-20 Atrium Medical Corporation Method and apparatus for application of a fresh coating on a medical device
US8367099B2 (en) 2004-09-28 2013-02-05 Atrium Medical Corporation Perforated fatty acid films
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060067976A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Formation of barrier layer
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US20070059350A1 (en) * 2004-12-13 2007-03-15 Kennedy John P Agents for controlling biological fluids and methods of use thereof
US8535709B2 (en) * 2004-12-13 2013-09-17 Southeastern Medical Technologies, Llc Agents for controlling biological fluids and methods of use thereof
US20060127437A1 (en) * 2004-12-13 2006-06-15 Misty Anderson Kennedy Semisolid system and combination semisolid, multiparticulate system for sealing tissues and/or controlling biological fluids
US8871712B2 (en) 2005-01-14 2014-10-28 Camurus Ab Somatostatin analogue formulations
US8920782B2 (en) * 2005-01-14 2014-12-30 Camurus Ab Topical bioadhesive formulations
US9649382B2 (en) * 2005-01-14 2017-05-16 Camurus Ab Topical bioadhesive formulations
AU2005325510B2 (en) * 2005-01-21 2009-07-02 Camurus Ab Pharmaceutical lipid compositions
US20060229364A1 (en) * 2005-03-10 2006-10-12 3M Innovative Properties Company Antiviral compositions and methods of use
US10918618B2 (en) 2005-03-10 2021-02-16 3M Innovative Properties Company Methods of reducing microbial contamination
WO2006099232A2 (en) * 2005-03-10 2006-09-21 3M Innovative Properties Company Antimicrobial pet wipes
TW200724134A (en) 2005-03-10 2007-07-01 3M Innovative Properties Co Antimicrobial compositions and methods
TW200719884A (en) 2005-03-10 2007-06-01 3M Innovative Properties Co Methods of treating ear infections
CN101217940B (zh) * 2005-06-06 2013-03-27 卡穆鲁斯公司 Glp-1类似物制剂
US20080219935A1 (en) * 2005-07-08 2008-09-11 Sang-Hoon Kwak Phase Transitive Breath Care Products
US20070020228A1 (en) * 2005-07-22 2007-01-25 Williams Terry N Method of using a biosealant device
WO2007016419A2 (en) * 2005-07-29 2007-02-08 The General Hospital Corporation Methods and compositions for reducing skin damage
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
EP1933991A4 (en) 2005-10-15 2012-05-02 Atrium Medical Corp HYDROPHOBIC NETWORKED GEL FOR BIOABSORBIBLE MEDICINAL CARRIER COVERS
US7858609B2 (en) 2005-11-28 2010-12-28 Marinus Pharmaceuticals Solid ganaxolone formulations and methods for the making and use thereof
EP1837020A1 (en) 2006-03-24 2007-09-26 Bioalliance Pharma Mucosal bioadhesive slow release carrier for delivering active principles
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
US20080075793A1 (en) * 2006-09-21 2008-03-27 Dunshee Wayne K Antiviral compositions and methods of use
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
BRPI0717721A2 (pt) 2006-11-28 2013-10-29 Marinus Pharmaceuticals "partículas complexadas de drogas, composição farmacêutica, uso de uma composição farmacêutica, partículas complexadas de droga estabilizadas no tamanho, método para a preparação de partículas estabilizadas da droga, composição farmacêutica sólida, comprimido oral ingerível e composição líquida em nanopartículas estabilizadas no tamanho"
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
GB0712316D0 (en) * 2007-06-26 2007-08-01 Entripneur Ltd A novel powder and its method of manufacture
GB0716385D0 (en) 2007-08-22 2007-10-03 Camurus Ab Formulations
US20090196905A1 (en) * 2008-02-06 2009-08-06 Spada Lon T Stabilization of mitochondrial membranes in ocular diseases and conditions
GB0815435D0 (en) * 2008-08-22 2008-10-01 Camurus Ab Formulations
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US20130029030A1 (en) 2010-03-15 2013-01-31 Kristian Larsen Method for promotion of hemostasis and/or wound healing
KR20130080435A (ko) * 2010-04-01 2013-07-12 파마네스트 아베 국소마취의 생체 점착성 조성물
EP2593141B1 (en) 2010-07-16 2018-07-04 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
CA2857982A1 (en) * 2011-12-05 2013-06-13 Camurus Ab Robust controlled-release peptide formulations
CN104220096B (zh) 2012-02-16 2017-10-20 技术创新动力基金（以色列）有限合伙公司 用于形成生物粘附基质的制剂和试剂盒
CA2874367C (en) 2012-05-25 2020-08-18 Camurus Ab Somatostatin receptor agonist formulations
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
WO2014015347A1 (en) * 2012-07-20 2014-01-23 Aegis Women's Health Technologies Compositions and methods for preventing infectious diseases in females
US9937164B2 (en) 2012-07-26 2018-04-10 Camurus Ab Opioid formulations
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271938A1 (en) * 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
BR112015027026A8 (pt) * 2013-04-26 2018-01-30 Bioglan Ab composição para uso na redução da formação de casca e na promoção da cicatrização
CA3001722A1 (en) 2015-10-16 2017-04-20 Marinus Pharmaceuticals, Inc. Injectable neurosteroid formulations containing nanoparticles
KR20230050474A (ko) 2016-08-11 2023-04-14 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
DE102018129419A1 (de) 2018-11-22 2020-05-28 Johannes Gutenberg-Universität Mainz Acrylat-Copolymer für galenische Anwendungen
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
EP4009982A4 (en) 2019-08-05 2023-08-09 Marinus Pharmaceuticals, Inc. GANAXOLONE FOR USE IN THE TREATMENT OF STATUS EPILEPTICUS
US11590151B2 (en) * 2019-08-30 2023-02-28 USpharma Ltd Pharmaceutical paste formulations for site specific application
KR20220134529A (ko) 2019-12-06 2022-10-05 마리누스 파마슈티컬스 인코포레이티드 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론
CN113350573B (zh) * 2021-06-07 2022-05-27 王健 一种具有骨诱导能力的多孔微球粘接剂及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH062667B2 (ja) * 1986-04-11 1994-01-12 積水化学工業株式会社 貼付剤
JPS63101316A (ja) * 1986-10-16 1988-05-06 Nichiban Co Ltd 医療用製剤
JP3046330B2 (ja) * 1990-07-16 2000-05-29 日東電工株式会社 貼付製剤

Also Published As

Publication number Publication date
NO964113D0 (no) 1996-09-27
AU685262B2 (en) 1998-01-15
CA2186750C (en) 2008-08-05
ES2135723T3 (es) 1999-11-01
WO1995026715A3 (en) 1995-11-16
CA2186750A1 (en) 1995-10-12
ATE180971T1 (de) 1999-06-15
DK0752855T3 (da) 2000-01-03
FI963867A (fi) 1996-11-27
EP0752855A1 (en) 1997-01-15
DE69510190T2 (de) 2000-01-27
JP4137179B2 (ja) 2008-08-20
DE69510190D1 (de) 1999-07-15
WO1995026715A2 (en) 1995-10-12
EP0752855B1 (en) 1999-06-09
FI963867A0 (fi) 1996-09-27
JPH09510980A (ja) 1997-11-04
AU2255095A (en) 1995-10-23
US5955502A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
NO964113D0 (no) Anvendelse av fettsyreestre som bioadhesive substanser
HUP0303881A2 (hu) Gyulladás kezelésére alkalmas zsíralkoholokat és zsírsav-észtereket tartalmazó gyógyszerkészítmények
IT1308613B1 (it) Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
NO934768D0 (no) Sammensetning av L-DOPA-estere
ATE15443T1 (de) Essbare, pharmazeutische zusammensetzungen und verfahren zur herstellung.
CA2219502A1 (en) Methods and formulations for modulating the human sexual response
CA2373852A1 (en) Oligosaccharide aldonic acids and their topical use
YU66600A (sh) Farmaceutski preparati koji mogu da budu gelirani
EA200301204A1 (ru) Фармацевтически активные производные нуклеозида, способ их получения, их применение (варианты) и содержащая их фармацевтическая композиция, способ профилактики и/или лечения заболеваний и нарушений млекопитающих (варианты), комбинация лекарственных средств и ее применение (варианты)
NZ307055A (en) Immunostimulating-wound healing compositions and methods for preparing and using same
WO2002064148A3 (en) Oral formulations containing mucopolysaccharide for small intestine delivery and their use in the treatment circulatory disorders
ATE193006T1 (de) Verfahren zur stabilisation der polyungesättigten fettsäuren und verwendung dieser stabilisierten produkten in therapie und in kosmetologie
ATE110723T1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
IE821796L (en) Waterless thixotropic composition
HUP0204097A2 (hu) Guanozin-3',5'-monofoszfát-foszfodiészteráz inhibitorok alkalmazása diabetikus fekélyek kezelésére szolgáló készítmények előállítására
HUP0004058A2 (hu) Készítmények és eljárások biológiai membránok permeabilitásának reverzibilis növelésére
WO2001068076A3 (en) D-enantiomer of dfmo and methods of use thereof for treating cancer
KR870006081A (ko) 신규 16,17-아세탈치환 프레그난 21-오익 에시드유도체 및 그의 제조방법
US5173511A (en) Method for treatment of allergies using glycerol ethers
EP0334281A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
NO178457C (no) Fremgangsmåte for fremstilling av et salisylsyreholdig preparat for behandling av hudsykdommer med avskalling
SU990225A1 (ru) Способ профилактики кислотного некроза зубов
JPH06263647A (ja) 過酸化脂質の抑制剤
KR910002787A (ko) 아크릴산 아미드유도체, 이들의 제조방법, 이들을 함유하는 약리학적 조성물 및 이들을 사용하는 약품
MX9605497A (es) Composicion para tratamiento en enfermedades inflamatorias cronicas.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application